A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
NCT ID: NCT04825678
Last Updated: 2024-09-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
240 participants
INTERVENTIONAL
2021-06-11
2023-09-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
NCT04252742
Efficacy of Erenumab on Functional Impact of Migraine
NCT04465357
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
NCT01952574
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
NCT02456740
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
NCT02483585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Erenumab
Erenumab
Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erenumab
Administered as a subcutaneous injection via the SureClick® Autoinjector Pen (AI/Pen).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has provided informed consent
* History of migraine (with or without aura) for ≥ 12 months before screening
* ≥ 4 migraine days per month on average across the 3 months prior to screening
* Treatment with 1 oral migraine preventive medication and/or concomitant use of OnabotulinumtoxinA injections for migraine prevention.
* Participant reports to their provider intolerance or insufficient response with their current preventative treatment
Exclusion Criteria
* Unable to differentiate migraine from other headaches
* Evidence of substance-related disorders
* Active chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain)
* No therapeutic response with \> 3 migraine preventive medication categories
* Used a prohibited medication, device, or procedure
* Other clinically significant disorder, condition, or disease
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rehabilitation and Neurological Services LLC
Huntsville, Alabama, United States
Elite Clinical Studies LLC
Phoenix, Arizona, United States
Neurology Center of North Orange County
Fullerton, California, United States
The Neurology Group
Pomona, California, United States
Mountain Neurological Research Center
Basalt, Colorado, United States
Mindscapes Counseling, LLC
Norwich, Connecticut, United States
Reliable Clinical Research, LLC
Hialeah, Florida, United States
Homestead Associates In Research Inc
Homestead, Florida, United States
New Age Medical Research Corporation
Miami, Florida, United States
The Community Research of South Florida
Miami Lakes, Florida, United States
Research Institute of Orlando
Orlando, Florida, United States
Pas Research
Tampa, Florida, United States
Georgia Institute for Clinical Research, LLC
Marietta, Georgia, United States
Chicago Headache Center and Research Institute
Chicago, Illinois, United States
College Park Family Care Center
Overland Park, Kansas, United States
Family HealthCare
Germantown, Maryland, United States
Neurology Center of New England
Foxborough, Massachusetts, United States
ActivMed Practices and Research, LLC
Lowell, Massachusetts, United States
Memorial Healthcare Foundation
Owosso, Michigan, United States
SRI International
Plymouth, Michigan, United States
Citizens Memorial Healthcare
Bolivar, Missouri, United States
Clinvest Research LLC
Springfield, Missouri, United States
Psych Care Consultants
St Louis, Missouri, United States
Albuquerque Clinical Trials Inc
Albuquerque, New Mexico, United States
Albany Medical College
Albany, New York, United States
Dent Neurosciences Research Center
Amherst, New York, United States
Northwell Health Physician Partners Neuroscience Institute at Great Neck
Great Neck, New York, United States
Island Neurological Associates
Plainview, New York, United States
Nuvance Health Medical Practice Primary Care Division of Neurology
Poughkeepsie, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Asheville Neurology Specialists PA
Asheville, North Carolina, United States
Onsite Clinical Solutions LLC
Charlotte, North Carolina, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Saint Lukes Neurology Associates
Bethlehem, Pennsylvania, United States
Clinical Trials of South Carolina
Charleston, South Carolina, United States
Premier Neurology
Greer, South Carolina, United States
Tri-State Mountain Neurology Associates
Johnson City, Tennessee, United States
Pearland Neurology Services PLLC
Houston, Texas, United States
Protenium Clinical Research
Hurst, Texas, United States
Houston Neurology Associates
Sugar Land, Texas, United States
Sugar Lakes Family Practice
Sugar Land, Texas, United States
Vaught Neurological Services
Crab Orchard, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20190389
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.